When is genetic testing for psychotropic medication recommended?

Genetic Testing for Psychotropic Medications: Current Recommendations

Genetic testing for CYP450 polymorphisms (specifically CYP2D6 and CYP2C19) is NOT recommended for routine use when initiating psychotropic medications, but should be considered selectively in patients who have already experienced treatment failures, significant adverse effects, or when prescribing specific high-risk medications.

Evidence-Based Framework for Testing Decisions

When Testing is NOT Recommended

Do not order routine genetic testing when starting first-line antidepressants in treatment-naïve patients. The EGAPP Working Group (CDC-sponsored guideline) explicitly discourages routine CYP450 testing for adults beginning SSRI treatment, citing insufficient evidence linking genotype results to improved clinical outcomes (remission rates, quality of life, or reduced adverse events) 1. Despite the availability of FDA-approved tests like the AmpliChip, no studies demonstrate that genotype-guided prescribing improves morbidity or mortality compared to standard empirical treatment.

When Testing Should Be Considered

Order CYP2D6 and CYP2C19 genetic testing in these specific clinical scenarios:

• Treatment-resistant depression: Patients who have failed 2+ adequate trials of antidepressants at therapeutic doses 2
• History of severe adverse drug reactions: Particularly intolerable side effects (severe nausea, serotonin syndrome, QT prolongation) that led to medication discontinuation 3
• Polypharmacy situations: When prescribing multiple CYP450-metabolized medications simultaneously, increasing risk of drug-drug interactions 2
• High-risk medications requiring precise dosing:
  • Carbamazepine (test HLA-A and HLA-B for Stevens-Johnson syndrome risk) 2
  • Oxcarbazepine (test HLA-B) 2
  • Phenytoin (test CYP2C9 and HLA-B) 2
  • High-dose fluoxetine or paroxetine for OCD (CYP2D6 poor metabolizers at risk for toxicity) 3

Genes with Established Clinical Utility

The International Society of Psychiatric Genetics consensus identifies only two pharmacokinetic genes with sufficient evidence for clinical implementation 2:

1. CYP2D6: Metabolizes tricyclic antidepressants, paroxetine, fluoxetine, venlafaxine, aripiprazole, risperidone, and others
2. CYP2C19: Metabolizes citalopram, escitalopram, sertraline, and tricyclic antidepressants

Key metabolizer phenotypes and their clinical implications:

• Poor Metabolizers (PM): Two inactive alleles → higher drug levels → increased adverse effects risk
• Intermediate Metabolizers (IM): One inactive allele → moderately reduced metabolism
• Extensive Metabolizers (EM): Normal metabolism (two active alleles)
• Ultra-rapid Metabolizers (UM): Gene duplications → very rapid metabolism → subtherapeutic levels at standard doses

Critical Limitations of Current Evidence

The evidence base has significant weaknesses that clinicians must understand:

Why routine testing lacks support:

• Single-dose studies in healthy volunteers showed clear genotype-drug level correlations, but studies in actual patients on steady-state SSRI doses showed inconsistent results 1
• Only 5 studies examined genotype-clinical response relationships; results were mixed and underpowered 1
• No randomized controlled trials demonstrate that genotype-guided treatment improves remission rates or quality of life compared to standard care 1
• The 2007 EGAPP guideline remains the most rigorous systematic evidence review, and no subsequent guidelines have overturned its core recommendation 1

Confounding factors not addressed in most studies:

• Concomitant medications that inhibit/induce CYP450 enzymes (including SSRIs themselves)
• Dietary factors affecting metabolism
• Other genetic variants in serotonin transporters and receptors
• Ethnic/racial differences in allele frequencies 1

Practical Implementation Approach

If you decide to order testing based on the scenarios above:

1. Order only CYP2D6 and CYP2C19 genotyping initially—these have the strongest evidence and most available dosing guidelines 2

2. Do not delay treatment waiting for results unless prescribing a medication with known serious genotype-related toxicity risk (e.g., carbamazepine without HLA testing)

3. Interpret results using established guidelines:

   • Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines
   • Dutch Pharmacogenetics Working Group (DPWG) guidelines
   • These provide specific dose adjustments for PM, IM, EM, and UM phenotypes 4

4. Recognize test limitations:

   • Results predict drug metabolism, not treatment response
   • Many factors beyond genetics affect outcomes
   • A "favorable" genotype does not guarantee efficacy 1

Common Pitfalls to Avoid

• Do not use genetic testing as a first-line tool to choose between antidepressants—clinical factors (symptom profile, comorbidities, prior response, side effect tolerance) remain more important
• Do not assume pharmacodynamic gene testing (COMT, FKBP5, HTR2A, SLC6A4, MTHFR) is clinically useful—these lack sufficient evidence and are not recommended 4
• Do not order multi-gene panels that include genes without established clinical utility—this increases cost without benefit 2
• Avoid "reactive testing" after a single medication trial failure—standard practice is to try 2+ medications before considering pharmacogenomic factors 5

Future Considerations

While current evidence does not support routine testing, preemptive testing (testing before any medication need) may become more viable as costs decrease and evidence accumulates 6. However, this remains investigational. Polygenic risk scores for antidepressant response show promise but lack sufficient predictive accuracy for clinical use, particularly in non-European populations 4.

The bottom line: Genetic testing is a potentially useful adjunct tool in complex cases, not a replacement for clinical judgment or standard empirical treatment approaches. The modest benefits demonstrated in some trials do not justify routine use in all patients starting psychotropic medications 4, 2.